Work

Estimated Annual Spending on Lecanemab and Its Ancillary Costs in the US Medicare Program

Year: 2023

Type: article

Abstract: This cross-sectional cost analysis uses data from the 2018 Health and Retirement Study to estimate the potential future Medicare spending and beneficiary costs for lecanemab.

Source: JAMA Internal Medicine

DOI: 10.1001/jamainternmed.2023.1749

Authors: Julia Cave Arbanas, Cheryl L. Damberg, Mei Leng, Nina Harawa, Catherine A. Sarkisian, Bruce E. Landon, John N. Mafi

Institutions: University of California, Los Angeles, RAND Corporation, VA Greater Los Angeles Healthcare System, Greater Los Angeles Geriatric Research Education and Clinical Center, Beth Israel Deaconess Medical Center, Harvard University

Language: English

Topic: Health Systems, Economic Evaluations, Quality of Life

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institute on Aging, National Institute of Mental Health, National Center for Research Resources, National Center for Advancing Translational Sciences

Awards: G2663518188, Leveraging Electronic Health Records to Measure and Reduce Harmful, Low-Value Care Among Older Adults, G343705321, G355665738, Center for HIV Identification, Prevention and Treatment Services, Identifying Approaches to Measure and Reduce Harmful, Low-Value Care Among Older Americans with Mild Cognitive Impairment and Dementia

OpenAlex ID: W4376129678

FWCI: 8.572

Cites: 6

Cited by: 42

Related to: 10